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Introduction: It is not possible to recover from chronic diseases; however, a healthy
lifestyle and correct adherence to therapy can avoid complications and co-morbidities. The
aim of this study was the cross-sectional evaluation, by means of a questionnaire, of real-
world data on the prevalence of non-adherence to metformin and atorvastatin oral therapies
in a sample of patients that attend community pharmacies in the Piedmont Region. The
secondary aim was to evaluate the presence of correlations between non-adherence and
a number of variables detected by the questionnaire.
Materials and Methods: Data were gathered from face-to-face interviews in six community
pharmacies in Piedmont. The questionnaire was divided into two sections: the first included the
Morisky, Green and Levine Medication Adherence Questionnaire (MAQ) (to assess therapy
adherence); the second included questions on gender, age, level of education and the pharmacy in
which the questionnaire was administered. Comparisons between proportions and mean values
were performed using the χ2 test. Modified Poisson regression with robust standard errors was
used for multivariate analysis. The level of significance was fixed at 0.05, CI at 95%.
Results: The sample analysed was composed of 408 subjects (receiving either metformin or
atorvastatin). According to MAQ, 62 patients were non-adherent (15% of the total cohort).
Crude and multivariate analysis did not show any statistically significant correlation between
gender, age, level of education and non-adherence. It emerged that there was a correlation
between non-adherence and being a customer of two of the pharmacies involved [PR = 3.31
(p=0.028) and PR = 3.11 (p=0.027)].
Conclusions: Community pharmacies can be an appropriate setting to identify non-adherent
patients. Therefore, healthcare professionals could realize an integrated and structured inter-
vention to improve adherence. However, MAQ could underestimate the number of non-
adherent patients. Further studies to test the association between non-adherence prevalence
and being the customer of a specific pharmacy should be performed.
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Introduction
It is well known that the impact of chronic diseases on the population is becoming
ever more evident. The Italian statistical yearbook reports that a significant portion
of the elderly people in Italy is affected by at least one chronic disease.1,2 Although
it is well known that it is not possible to recover from these diseases, a healthy
lifestyle and correct adherence to therapy can avoid complications and co-
morbidities.3 However, correct adherence to therapy is a complex and multifaceted
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behaviour and most failures in disease treatment arise from
inaccurate adherence to therapy.3–5 Even if the definition
of non-adherence is well known, no universal and ongoing
high impact model has been identified to prevent and
quantify this negative behaviour.6 It is estimated that the
percentage of people that are non-adherent to oral antidia-
betic drugs is 57%4 and that the same figure for lipid-
lowering treatments is 53%.7
In Italy, a Legislative Decree8 was designed to promote
the role of community pharmacies as a place where
patients can access chronic-disease-prevention and drug-
adherence services. In this regard, Federfarma Piedmont,
the Orders of Pharmacists of Piedmont and the University
of Turin have joined forces to create the “Farmacia di
Comunità” (Community Pharmacy) project. This project’s
aim is to present a new role for community pharmacies in
the it-NHS (Italian National Health Service), using
a structured intervention-model.9 The intervention-model
is composed of three phases:
● pharmacist training in disease, therapy and the admin-
istration of questionnaires;
● administration of a questionnaire followed by struc-
tured subject/patient counselling. The questionnaires
are written in collaboration with experienced epide-
miologists, clinicians and community pharmacists;
● evaluation of the impact of the intervention-model.
The “Community Pharmacy” intervention model also
includes a number of satellite studies to test the feasibility
of the model and analysis techniques. The present study
has been performed as one of these pilot studies.
The aim of this study was the cross-sectional evalua-
tion of real-world data on the prevalence of non-adherence
to metformin and atorvastatin oral therapies in a sample of
patients that attend community pharmacies in the
Piedmont Region. The secondary aim was the evaluation
of the presence of correlations between non-adherence and
a number of variables detected by the questionnaire.
Materials and Methods
The study was designed as a cross-sectional survey. Data
were gathered from face-to-face interviews by means of
questionnaires10 performed by adequately trained research-
ers. The interviews were carried out in six community
pharmacies in Piedmont (recruited on a voluntary basis)
that were chosen from a panel of pharmacies with experi-
ence in the gathering of data from questionnaires.
The recruitment period was from April 2016 to
May 2017. The patients enrolled were all those that
entered one of the pharmacies, that were involved, with
an it-NHS prescription of metformin (any dosage), or
atorvastatin (any dosage) and that accepted to participate
in the study. The two drugs were chosen because of the
high prevalence of the two diseases (diabetes and hyperch-
olesterolemia), and the estimated low therapy adherence.6
The questionnaire was divided into two sections:
● The first section included theMorisky, Green and Levine
Medication Adherence Questionnaire (MAQ),11 which
is a questionnaire consisting of four closed-ended ques-
tions. With two positive responses, the subject is con-
sidered non-adherent to therapy.
● The second section included questions on gender,
age, level of education and the pharmacy in which
the questionnaire was administered.
Statistical Methods
PR (prevalence ratio) and the percentage prevalence were
the two indicators used for the crude and the multivariate
analysis. Prevalence is considered to be the tool that is least
affected by overestimation, in cross-sectional studies, when
the prevalence of the event studied is elevated (>5%).12 The
normality of data distribution was evaluated by performing
the Shapiro–Wilk test. Comparisons between proportions
and mean values were performed using the χ2 test.
Modified Poisson regression with robust standard errors
was the model used for multivariate analysis. The level of
significance was fixed at 0.05, CI at 95%. Statistical analysis
was performed using Stata14 ® (Corp. 2015. Stata Statistical
Software: Release 14. College Station, TX: StataCorp LP).
Results
The prevalence of non-adherent subjects taking atorvasta-
tin and the one of those taking metformin was similar
[p=0.7]. Therefore, to not decrease the statistical power
of the study, data on the two drugs were analysed together.
Descriptive Statistics
The sample analysed was composed of 408 subjects.
The mean age was 69 years with 46% of the subjects
being under 70 years old. Forty-one percent of the inter-
viewees were female (Table 1). There were no significant
age-group differences between men and women (p=0.9).
The levels of education in men and women did not vary
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(p=0.09), while younger subjects (<70 years old) had
a higher level of education than older subjects (p<0.001).
Neither age distribution (p=0.529), nor gender (p=0.67)
varied across pharmacies, while the distribution of educa-
tional level was significantly different (p<0.001).
One hundred and fifty subjects (37% of the cohort)
gave a positive answer to at least one question in the
MAQ, and 62 subjects (15%) were considered non-
adherent to therapy (with at least two positive answers).
Of these, 55 subjects (13% of the cohort) answered “yes”
to two questions and 7 (2%) to three.
An analysis of each answer to the MAQ led to the
observation that a positive response to question 1 or question
2 was more frequent when the subject was found to be non-
adherent to therapy (according to the score). The difference
in the prevalence of positive answers in adherents and non-
adherents was significant for all items (Table 2).
Each answer was analysed in order to evaluate possible
correlations with gender, age, education level and pharmacy
(Table 3). As seen in Table 3, there was no correlation
between gender, age, education level and pharmacy in posi-
tive answers to single items.
Multivariate Analysis
The multivariate analysis confirmed the results of the
crude analysis regarding gender, age and level of educa-
tion: there was no significant correlation between these
variables and the increasing prevalence rate of non-
adherence (Table 4).
It emerged that there was a correlation between non-
adherence and being a customer of pharmacies number 3
and 5 [respectively, PR = 3.31 (CI 95% 1.13–9.66;
p=0.028) and PR = 3.11 (CI 95% 1.13–8.55; p=0.027)].
Discussions
The results showed that 15% of the patients recruited in the six
community pharmacies involved were non-adherent to thera-
pies. This rate is lower than the figure estimated in the litera-
ture, which is about 50–60% of non-adherence prevalence for
the two drugs investigated.4–7 The underestimated prevalence
of non-adherence may be due to a selection bias; patients
recruited in pharmacies may be intrinsically more adherent
to the baseline than those reported in the literature. There may
also be a social desirability bias present: patients are not
inclined to declare their non-adherence to a healthcare
professional.13 This bias may have led patients to give nega-
tive responses in the face-to-face interview simply to avoid
judgment by a healthcare professional. In the future, it may be
interesting to investigate the extent of the social desirability
bias in face-to-face interviews that use the MAQ.
The sample size of the interviewed population was small,
therefore the single-answer analysis showed that gender is
not correlated with non-adherence to therapy. This type of
difference is usually only detectable in large cohorts.14
Furthermore, age did not appear to be associated with non-
adherence in this study. This evaluation may be flawed as
some variables, such as treatment complexity and the possi-
bility of aid being given by relatives or caregivers, were not
considered. Although education level did not appear to be
correlated with non-adherence in the present study, literature
reports show that a low level of education is strictly related to
non-adherence to therapy.15 The absence of this association
may be due to the low statistical power of the study or
possibly to other non-investigated confounders.
The increased prevalence of non-adherence in associa-
tion with being the customer of a specific pharmacy is an
interesting result. Indeed, our results show that there seems
to be an association between the pharmacy in which the
questionnaire was administered and the prevalence rate of
being non-adherent. More analysis and future studies
could be performed to investigate this correlation.
Using a validated questionnaire such as the Morisky-
Green-Levine questionnaire, a cross-sectional study was car-
ried out in Italy for the first time, to our knowledge, to assess
therapy adherence in chronic patients. Indeed, entering on
Table 1 Population Distribution per Gender, Age, Education and
Pharmacies
Variable Subjects (%)
Gender Women 167(41%)
Men 241 (59%)
Age <65 106 (26%)
65–69 82 (20%)
70–75 73 (18%)
>75 147 (36%)
Level of education Primary school 140 (34%)
Middle school 133 (33%)
High school 102 (25%)
University 33 (8%)
Pharmacy 1 110 (27%)
2 81 (20%)
3 32 (8%)
4 90 (22%)
5 27 (7%)
6 68 (17%)
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PubMed the words: “Morisky; pharmacies; chronic; Italy” no
items have been found. It is important to underline that only
few studies at the international level used pharmacies as
a recruiting centre to assess patients’ adherence to therapies.
The comparison between these studies and ours is complicated
by the significant differences among the national NHSs.16–18
Strengths and Limits of the Study
Face-to-face interviews were used to collect data by a pre-
set questionnaire. The data collection was carried out by
researchers purposely trained. The pharmacy role to detect
non-adherent subjects was highlighted by this data collec-
tion method.
Table 4 Crude and Multivariate PR – Poisson Regression Modified with Robust Standard Errors
Subjects (%) Non-
Adherent
Subjects (%)
Crude PR
(95% CI)
Multivariate PR
(95% CI)
Multivariate p-value
Gender Women 167(41%) 27 (16%) 1 1 -
Men 241 (59%) 35 (14%) 0.89 (0.56–1.44) 0.88 (0.53–1.44) 0.663
Age <65 106 (26%) 17 (16%) 1 1 -
65–69 82 (20%) 10 (12%) 0.76 (0.34–1.66) 0.81 (0.36–1.7) 0.5
70–75 73 (18%) 10 (14%) 0.60 (0.27–1.32) 0.75 (0.33–1.76) 0.86
>75 147 (36%) 25 (17%) 1.33 (0.72–2.4) 1.10 (0.57–2.11) 0.64
Level of education Primary school 140 (34%) 22 (16%) 1 1 -
Middle school 133 (33%) 16 (12%) 0.76 (0.40–1.45) 0.79 (0.40–1.52) 0.49
High school 102 (25%) 18 (18%) 1.12 (0.60–2.09) 0.94 (0.47–1.81) 0.86
University 33 (8%) 6 (18%) 1.16 (0.47–2.85) 0.77 (0.27–2.22) 0.64
Pharmacy 1 110 (27%) 9 (8%) 1 1 -
2 81 (20%) 12 (15%) 1.81 (0.76–4.29) 1.76 (0.73–4.22) 0.20
3 32 (8%) 8 (25%) 3.05 (1.17–7.91) 3.31 (1.13–9.66) 0.028
4 90 (22%) 13 (14%) 1.76 (0.75–4.13) 1.80 (0.76–4.22) 0.18
5 27 (7%) 7 (26%) 3.16 (1.18–8.50) 3.11 (1.13–8.55) 0.027
6 68 (17%) 13 (19%) 2.33 (0.99–5.46) 2.40 (0.99–5.88) 0.053
Table 2 Frequency of Positive Responses to the MAQ, Sorted by Item
MAQ Question Frequency of
Positive
Responses
Frequency of Positive
Responses in Non-
Adherents
Frequency of
Positive Responses
in Adherents
p-value Difference Between Positive
Responses in Adherents and in Non-
Adherents*
Answer1 121 (30%) 60 (97%) 61 (18%) <0.001
Answer2 71 (17%) 57 (92%) 14 (4%) <0.001
Answer3 12 (3%) 5 (8%) 7 (2%) 0.01
Answer4 15 (4%) 9 (15%) 6 (2%) <0.001
Notes: *p-value chi2.
Table 3 Correlation by Chi2 p-Value Between the Probability of Positive Responses by Item and Gender, Age, Education and Pharmacy
MAQ
Question
Frequency of
Positive
Responses
Gender Correlation
with the Answer *
Age Correlation
with the Answer *
Education Correlation
with the Answer *
Pharmacy Correlation
with the Answer *
Answer1 121 (30%) 0.15 0.08 0.233 0.83
Answer2 71 (17%) 0.19 0.09 0.497 0.11
Answer3 12 (3%) 0.24 0.79 0.458 0.11
Answer4 15 (4%) 0.94 0.79 0.869 0.24
Notes: *p-value chi2.
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Data present in literature suggest significant differ-
ences between the adherence to oral treatment for dia-
betes and the one to oral lipid-lowering treatment.4–7
Clinical practises have observed that diabetic patients
perceive their condition as a pathology whereas patients
treated with lipid-lowering drugs often do not. The latter
are less aware of their pathological condition leading to
less care in the adherence. The effect of therapy interrup-
tion in this case may not be as immediate as it is for
diabetic patients. This effect causes the perception that
glucose-lowering drugs are more essential than lipid-
lowering drugs.4,19–21
However, in apparent contrast with the data in the
literature, the present study highlighted that the prevalence
of non-adherence in the two cohorts is similar. Therefore,
to increase the statistical power of this study, metformin-
treated and atorvastatin-treated subjects were aggregated.
Moreover, the generalisability of the results is not
easily definable.
The sociodemographic data of the subjects that did not
willing to take part in the study were not collected.
Furthermore, in this pilot study, few factors, possibly
responsible for the no adherence, were taken into consid-
eration by the questionnaire. Future studies will be needed
to investigate further patient habits and how these factors
impact on their adherence to the therapies (such as the
number of medications taken, how long patients have been
taking the medication, ADR, . . . ).
This kind of study (cross-sectional survey) does not
allow us to evaluate the causal inference about the
variables that affect non-adherence. We can only sup-
pose that the correlation found in the present study
(non-adherence and being a customer of two of the
pharmacies involved) may be present due to the differ-
ent sociodemographic characteristics of the areas in
which the pharmacies are located or to the different
expertise of the pharmacists. Further studies are needed
to investigate this correlation.
Conclusions
It can be concluded that community pharmacies can be used to
identify non-adherent patients. Indeed, 62 non-adherent
patients have been identified in the pharmacies involved.
Therefore, healthcare professionals could realize an integrated
and structured intervention to improve patients’ adherence.
Many studies have demonstrated the utility and efficacy of
the community pharmacy in improving patients’
adherence.22,23 The structured counselling is the main tool
for the community pharmacist to apply to improve patient
adherence.24 However, the counselling of the pharmacist has
to be built on solid foundations. It is essential that pharmacists
be trained to intervene efficiently in different conditions.25
Better results could be achieved if pharmacists would be part
of a multidisciplinary team.
However, MAQ used in the community pharmacy set-
ting could underestimate the number of non-adherent
patients. Future studies are needed to identify more effec-
tive methods for the identification of non-adherent subjects
in community pharmacies.
Moreover, this study has also identified a possible cor-
relation between non-adherence prevalence and being the
customer of a specific pharmacy. Further studies to test the
association between these two variables should be per-
formed. If this association is confirmed, the variable
must be taken into consideration in all studies that use
community pharmacies as recruiting centres.
Increasing the sample size to grant the statistical power to
analyse the two cohorts separately (patients treated with
atorvastatin and metformin) is one of the goals for the future.
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